FDA unveils new pathway for rare disease treatments
The Trump administration on Monday released detailed guidance for approving the first bespoke medicines crafted to treat patients’ individual…
#NewsBeep #News #Topstories #biotech #CRISPR #FDA #Genetherapy #gene-editing #Headlines #rarediseases #STAT+ #TopStories
https://www.newsbeep.com/406570/
Karnataka's bioeconomy reached 9 billion in 2025, up from 1 billion two years earlier, according to the Karnataka Bioeconomy Report 2025 released by the state's IT/BT ministry in collaboration with Association of Biotechnology Led Enterprises. https://economictimes.indiatimes.com/tech/startups/karnatakas-bioeconomy-reaches-39-billion-in-2025-report/articleshow/128719125.cms #India #Tech #Biotech #Startups
Vaccine Development Sees Setbacks Amid Funding Shifts and Industry Contraction
See how new government funding rules are causing vaccine companies like Moderna to cut jobs and stop research. Learn what this means for future medicines.
#VaccineResearch, #ModernaLayoffs, #mRNA, #Biotech, #HealthPolicy
https://newsletter.tf/how-changes-to-vaccine-funding-affect-research-and-jobs/
More than 800 jobs cut at Moderna and other vaccine companies as funding changes. This is a big drop in research staff.
#VaccineResearch, #ModernaLayoffs, #mRNA, #Biotech, #HealthPolicy
https://newsletter.tf/how-changes-to-vaccine-funding-affect-research-and-jobs/
FDA Clears FluoGuide's IND for FG001
FluoGuide has obtained FDA clearance for its Investigational New Drug (IND) application regarding FG001 in high-grade glioma. This regulatory step transitions the asset into late-clinical development towards U.S. registration. The company also confirmed FDA alignment on the U.S. Phase II trial design and key elements of the subsequent Phase III program.
Vaccine Research Sees Reductions Amid Funding Shifts and Policy Debates
Vaccine research and jobs are decreasing as funding and policies shift. Learn why this matters for future health and US industry.
#VaccineResearch, #FundingCuts, #Biotech, #USManufacturing, #PublicHealth
https://newsletter.tf/vaccine-research-funding-policy-changes/
Vaccine research and jobs are being cut. Companies are doing less studies, and some planned factories will not be built. This is happening because of changes in government money and rules. Some people think this is bad for the country's future health and manufacturing.
#VaccineResearch, #FundingCuts, #Biotech, #USManufacturing, #PublicHealth
https://newsletter.tf/vaccine-research-funding-policy-changes/
US Government Cuts Impact mRNA Vaccine Research and Future Pandemic Preparedness
The US government is cutting funds for mRNA vaccine research. This could affect future pandemic plans and new disease treatments.
#mRNA, #VaccineResearch, #PublicHealth, #USGovernment, #Biotech
https://newsletter.tf/us-government-cuts-mrna-vaccine-research/
Scientists are worried because the US government is giving less money to research for mRNA vaccines. This technology helped make COVID-19 vaccines fast. Experts say this could make it harder to fight future sicknesses and create new medicines.
#mRNA, #VaccineResearch, #PublicHealth, #USGovernment, #Biotech
https://newsletter.tf/us-government-cuts-mrna-vaccine-research/
Bringing therapeutics to market is complex. Scaling your operations shouldn't be. 🧬
The new BioVertex Consulting website is live!
From early-stage strategy to clinical program management and Operational Excellence, we help you execute flawlessly.
💻 Accelerate your pipeline: www.biovertexconsulting.com
What operational hurdle is your team facing right now? Reply or DM us! 👇
Leonardo V. Castorina (@DrLeucine)
Microsoft Research와 Adaptive Biotech이 공동 발표한 새로운 프리프린트 논문에서는 HLA 대립유전자가 TCR Vβ 세그먼트 사용 선호에 어떤 편향을 만드는지 분석했습니다. 이는 생명정보학 및 AI 기반 항체 연구에 중요한 통찰을 제공합니다.
Le cas Abivax (Biotech)
Investir dans les biotechs françaises : opportunité en or ou pari risqué ? 🧪
Aujourd'hui, on décortique le dossier #Abivax. Entre son introduction au Nasdaq et les phases cliniques de l'Obefazimod, la société est à un tournant majeur pour le traitement des maladies inflammatoires chroniques (MICI).
Voici pourquoi cette valeur attire tous les regards des investisseurs spécialisés. 1/4
#Bourse #Investissement #Biotech #Finance #Abivax #Obefazimod #AnalyseFinancière
🧠💻 Researchers used electrical pulses to "coach" lab-grown clusters of #brain cells to balance a virtual pole.
This proof of concept shows that living neural tissue can be tuned like a biological #computer, opening new doors for studying how the brain learns – and what happens when neurological diseases get in the way.
#neuroscience #biotech #AI #science #biology #stem #research #discovery
Hello #Fediverse! We are BioVertex Consulting, joining the conversation on #LifeSciences strategy and operational excellence. 🧬
We bridge the gap between groundbreaking science and disciplined execution for #Biotech, #Pharma, and #MedTech firms globally.
What we do:
🔹 Program & Alliance Management
🔹 Fractional Leadership (VP Ops/CMO)
🔹 Process Optimization
🔹 Development Roadmaps
Looking to connect with #Science, #VentureCapital, and #HealthTech innovators! 🚀
Coegin Pharma Executes Directed Issues
The company has carried out directed issues totaling approximately SEK 12 million. The subscription price is set at SEK 3.25 per share. This corresponds to a discount of approximately 15 percent compared to the volume-weighted average price (VWAP) of the company share during the preceding ten trading days.
Oncopeptides Announces Rights Issue
Oncopeptides executes a rights issue of approx SEK 200 million. Proceeds will support Pepaxti commercialization in Europe and advance the glioblastoma project to clinical development, including a window-of-opportunity study. HealthCap VIII LP commits SEK 20 million.
Wenn Algorithmen beim Design neuer Viren helfen können, müssen wir die Sicherheitsbarrieren und ethischen Leitplanken von KI-Modellen grundlegend neu bewerten.
Erfahre mehr in meinem neuen Beitrag auf @BASICthinking
https://www.basicthinking.de/blog/2026/02/18/ki-viren-erschaffen/
#KI #CyberSecurity #BioTech #KünstlicheIntelligenz #AI #Sicherheit #Ethik #TechNews
Magle Group Issues Profit Warning
Magle Group announces a profit warning ahead of Q4 results. Following a strategic refocus in January 2026, Q4 2025 EBITDA is estimated at approximately negative SEK 42 million, down from SEK 20 million in 2024. The result reflects restructuring costs, impairments, and asset write-downs aligned with the company's commitment to operational discipline.
Synartro Reports LPLV in Phase I/IIa Study
Synartro announces the last participant's last visit in the Phase I/IIa clinical trial of SYN321, an intra-articular treatment for knee osteoarthritis. Initiated in August 2025, the study involved 35 participants across four cohorts to evaluate safety, tolerability, PK, and early efficacy.
Morphic Agriculture tracks the biological exertion and flow of farms in real-time to ensure physical reality matches every contract. 🧬🌾
By using the QOE-NEFSM swarm, DOPA-TECH provides a "Grounding Index" for exports, ensuring that what is signed in a boardroom is verified on the ground. No more PR farming—just biological truth.
#AgTech #BioTech #MorphicAgriculture #SustainableFarming #Transparency
